WuXi AppTec Peptide Facility Receives PMDA Approval

WuXi AppTec Peptide Facility Receives PMDA Approval

By, Admin 22 April 2024

Overview

With peptides, oligos and peptide conjugates continuing to attract drug developer interest and industry capacity in short supply, WuXi AppTec recently reported its Changzhou site has been approved by Japan’s PMDA [Pharmaceuticals and Medical Devices Agency).

About Inspection

  • The three-day inspection was passed without any major findings and follows on from the continuing expansion plans announced late last month during DCAT.  
  • The new investments cover several large sites, including the 169-acre active pharmaceutical ingredient (API) manufacturing facility in Taixing, alongside existing drug-product manufacturing facilities in Wuxi City, China, and Couvet, Switzerland, and forthcoming sites in Middletown, Delaware, and Tuas, Singapore.

Phase I

  • Phase 1 of the Taixing site – which spans an initial 81 acres with nine manufacturing plants, three of which are now in use ­– has been operational since January 2024. 
  • Including the new site, the company’s total reactor volume for API production will increase to 3,773 m3 by the year’s end (2024).

In response to continuing demand-side pressure for peptides and GLP-1 drugs, WuXi TIDES [the company’s peptide unit] has also tripled its peptide manufacturing capacity. The company’s total solid-phase peptide synthesis (SPPS) reactor volume has reached 32.5KL, with plans to further enhance SPPS capacity in Taixing and at its upcoming Singapore site [Phase 1 will open in 2026]. Significantly, the CDMO reported during its DCAT presentation that it now supports some 48 peptide-based drugs in various phases from preclinical to commercial.

Manufacturing Capabilities

  • It was also confirmed that company’s oligonucleotide manufacturing capabilities, with 27 lines currently operational across two sites, supports over 160 projects. 
  • These include all the common modalities ASO, siRNA, and PMO, and is supported by a team of over 600 scientists.

Drug-Product Manufacturing

  • Similarly, drug-product manufacturing continues to grow with the introduction of high-potency (HP) lines [occupational exposure limit OEL of 10 ng/m3] for both sterile injectables and oral solids including tablets and capsules. 
  • In fact, by the end of 2024, WuXi will have five aseptic filling lines suitable for sterile injectables, eye-drops, and inhalants. 
  • Meanwhile, at the company’s drug-product site in Couvet (Switzerland), plans are underway to double tablet and capsule production capacity, add a parenteral line, a lipid nanoparticle (LNP) platform, and a spray dryer.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!